Medication info

Hanbika Tablet 5/20 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
(Co., Ltd.) Hanpung Pharmaceutical
Appearance
White round film-coated tablet
Packaging
30 tablets/PTP [10 tablets/PTP x 3]
Approval status
Expired

MFDS item code 201906358 · Approved 2019.09.09

This product's status changed to Expired on 2024.09.09. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted; however, if blood pressure is not controlled with monotherapy using the individual components, a direct switch to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients Who Should Not Receive This Medicine under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and coexisting diseases. Blood pressure should be monitored closely and more frequently in older adults.
Child dose
∘Pediatric patients: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
(Co., Ltd.) Hanpung Pharmaceutical

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to effectively lower blood pressure in patients with essential hypertension who do not achieve sufficient blood pressure control with monotherapy of either amlodipine or olmesartan medoxomil. This helps reduce the risk of cardiovascular diseases and improve the patient's health.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted; however, if blood pressure is not controlled with monotherapy using the individual components, a direct switch to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: Administer to patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients Who Should Not Receive This Medicine under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and coexisting diseases. Blood pressure should be monitored closely and more frequently in older adults.

Child dose

∘Pediatric patients: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be used by patients with allergies to any of its components, or those who are pregnant or breastfeeding, patients with severe liver disease or certain heart conditions, patients undergoing renal dialysis, those in shock, and some diabetic patients. Patients with a lack of bodily fluids or salts may experience low blood pressure, so it is essential to closely monitor their condition when starting treatment, and appropriate measures should be taken if hypotension occurs. Patients with heart or vascular problems should exercise particular caution as rapid vascular dilation may lead to hypotension. It should be used cautiously in patients with heart failure or impaired kidney function, and those with decreased liver function should also be cautious while on this medication. Adverse reactions such as dizziness, headache, low blood pressure, indigestion, skin rashes, etc., may occur during treatment, so any unusual symptoms should be reported to a physician. This medication can interact with various other drugs, so it is crucial to inform your physician of any medications currently being taken, especially grapefruit juice, which is not recommended to be taken with this drug. It should be avoided during pregnancy, and breastfeeding mothers should consider stopping breastfeeding or the medication as it may be transmitted through breast milk. It is not recommended for children under 18 years of age as safety and efficacy have not been established. Elderly patients may have impaired liver, kidney, or heart function, so starting with lower doses and closely monitoring their condition is advised. In case of overdose, severe hypotension, vascular dilation, tachycardia, etc., may occur, necessitating immediate medical attention. This medication should be stored away from moisture, heat, and light, in a place inaccessible to children, and transferring it to a different container is not recommended.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory impairment
  • syncope
Show 77 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • epigastric pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • lumbago
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial edema
  • decreased blood potassium
  • increased blood creatinine
  • increased blood uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • cerebral infarction exacerbation
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • angioedema
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • non-cardiogenic pulmonary edema
  • hypotension
  • tachycardia
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature to preserve the effectiveness of the medication.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

30 tablets/PTP [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.